These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 3888944)

  • 1. Safety and pharmacokinetics of ceftazidime in patients with chronic hepatic dysfunction.
    Pasko MT; Beam TR; Spooner JA; Camara DS
    J Antimicrob Chemother; 1985 Mar; 15(3):365-74. PubMed ID: 3888944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis.
    Turner A; Pedler SJ; Carswell F; Spencer GR; Speller DC
    J Antimicrob Chemother; 1984 Nov; 14(5):521-7. PubMed ID: 6392281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy.
    Walstad RA; Dahl K; Hellum KB; Thurmann-Nielsen E
    Eur J Clin Pharmacol; 1988; 35(3):273-9. PubMed ID: 3053209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of hemodialysis on ceftazidime pharmacokinetics.
    Nikolaidis P; Tourkantonis A
    Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
    Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
    Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and safety of ceftazidime in the neonate.
    Mulhall A; de Louvois J
    J Antimicrob Chemother; 1985 Jan; 15(1):97-103. PubMed ID: 3882658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
    Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancing age and acute infection influence the kinetics of ceftazidime.
    Ljungberg B; Nilsson-Ehle I
    Scand J Infect Dis; 1989; 21(3):327-32. PubMed ID: 2667099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of ceftazidime in patients with liver cirrhosis and ascites.
    el Touny M; el Guinaidy MA; Abd el Barry M; Osman L; Sabbour MS
    J Antimicrob Chemother; 1991 Jul; 28(1):95-100. PubMed ID: 1769947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.
    Halabi A; Maatouk H; Siegler KE; Faisst N; Hinrichsen H
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):290-6. PubMed ID: 27128835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():25-32. PubMed ID: 10702884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.
    Panomvana D; Kiatjaroensin SA; Phiboonbanakit D
    Clin Pharmacokinet; 2007; 46(10):859-66. PubMed ID: 17854235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
    Miller AA; Murry DJ; Owzar K; Hollis DR; Lewis LD; Kindler HL; Marshall JL; Villalona-Calero MA; Edelman MJ; Hohl RJ; Lichtman SM; Ratain MJ
    J Clin Oncol; 2007 Jul; 25(21):3055-60. PubMed ID: 17634483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction.
    Farthing MJ; Alstead EM; Abrams SM; Haug G; Johnston A; Hermann R; Niebch G; Ruus P; Molz KH; Turner P
    Postgrad Med J; 1994 May; 70(823):363-6. PubMed ID: 8016009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
    Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
    Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics of ceftazidime injected peritoneally in continuous ambulatory peritoneal dialysis].
    Ryckelynck JP; Vergnaud M; Hurault de Ligny B; Allouche G; Malbruny B; Morel C
    Pathol Biol (Paris); 1986 May; 34(5):328-31. PubMed ID: 3534700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The pharmacokinetics of ceftazidime in the burned patients].
    Zong G; Xiao G; Zhang Y
    Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi; 1994 Sep; 10(5):385-8. PubMed ID: 7712387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.
    Hebert MF; Smith HE; Marbury TC; Swan SK; Smith WB; Townsend RW; Buell D; Keirns J; Bekersky I
    J Clin Pharmacol; 2005 Oct; 45(10):1145-52. PubMed ID: 16172179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.